Caligor supporting Puma's expanded access program for breast cancer therapy

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Voyagerix)
(Image: iStock/Voyagerix)

Related tags: Breast cancer, Cancer, Oncology

Caligor Opco LLC is providing regulatory and logistical management for Puma Biotechnology’s expanded access program (EAP) for its investigational breast cancer therapy, neratinib.

This program will provide access to neratinib for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors while neratinib is still an investigational agent​,” Karen Frascello, vice president of business development at Caligor Opco.

Caligor Opco manages regulatory, logistics, and supply chain needs for global access programs. It also sources, stores, and distributes comparator drugs for clinical trials.

Frascello explained the company helps advance the program by “efficiently meeting the needs of all stakeholders​,” which enables Puma to focus on neratinib clinical development and ongoing regulatory activities.

Caligor will also help Puma manage health care professional (HCP) requests for neratinib.

We will also communicate with HCPs to help manage neratinib treatment and facilitate access to re-supply of neratinib for patients​,” added Frascello.

Our clinical operations team will respond to general inquiries from US HCPs; explain the EAP requirements to HCPs; and assist in answering regulatory questions as well as those related to Institutional Review Board (IRB) approvals​,” she explained.

Additionally, the company will work the Puma’s drug supply personnel to coordinate neratinib shipments to physician practices or hospitals.

Currently, the US EAP is open and accepting unsolicited patient access requests to neratinib from HCPs.  

Frascello explained the program will close “if and when​” neratinib gains FDA approval. “The specific parameters of the program are set forth by Puma Biotechnology,​” she added.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars